11 research outputs found

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

    Anecdotal to actual: identifying users of learning development to inform future practice

    Get PDF
    With increasing pressure on universities to ensure their students are graduating with a good honours degree, understanding where Learning Development sits in the university and its impact is arguably becoming more important. The Centre for Learning and Study Support (CLaSS) at De Montfort University, Leicester, has investigated data, collected since 2010, on student engagement with our Learning Development Service. The study aimed to discover the diversity of students availing of learning development, with regards to characteristics such as: gender, ethnicity, disability, age, parental education and module marks. The data presented shows how CLaSS can justifiably engage in university wide discussions about retention and achievement, as well as widening participation agendas. It compares, where possible, who is using CLaSS to the diversity of students within the university. Initial findings are presented, with discussion about how findings have impacted practice, with a particular focus on the attainment gap. From close analysis of the findings which demonstrate a lack of engagement by males with learning development, the paper proposes why this may be the case and offers insight into recent activities to try and reduce the gender gap. Overall, the paper recognises how interpretation of and greater awareness of our user diversity has informed our team strategy and future direction
    corecore